Movement Alert｜Definium Therapeutics Rises 5.09% in Regular Trading, Phase 3 Clinical Success and Major Financing Boost Market Confidence

Market Focus07-09

On July 9, Definium Therapeutics rose 5.09% in regular trading, trading at $47.34 per share with turnover of $67.50 million.

The rally continues to be driven by the companys core product DT120 orally disintegrating tablet achieving positive topline results in its pivotal Phase 3 EMERGE study for major depressive disorder. The study met its primary endpoint and all key secondary efficacy endpoints, demonstrating statistically significant improvement over placebo with a favorable safety profile. Following the data readout, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.

Additionally, the company closed an upsized public offering of approximately 23.7 million shares at $34 each, raising gross proceeds of $805 million, including the full exercise of underwriter overallotment options. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. The combination of validated clinical data and strengthened financial position continues to support upward momentum in the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192883916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 23:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192883916","market":"us","top_or_hot":-1,"title":"Movement Alert｜Definium Therapeutics Rises 5.09% in Regular Trading, Phase 3 Clinical Success and Major Financing Boost Market Confidence","media":"Market Focus","content":"<p><p>On July 9, Definium Therapeutics rose 5.09% in regular trading, trading at $47.34 per share with turnover of $67.50 million.</p><p>The rally continues to be driven by the companys core product DT120 orally disintegrating tablet achieving positive topline results in its pivotal Phase 3 EMERGE study for major depressive disorder. The study met its primary endpoint and all key secondary efficacy endpoints, demonstrating statistically significant improvement over placebo with a favorable safety profile. Following the data readout, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.</p><p>Additionally, the company closed an upsized public offering of approximately 23.7 million shares at $34 each, raising gross proceeds of $805 million, including the full exercise of underwriter overallotment options. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. The combination of validated clinical data and strengthened financial position continues to support upward momentum in the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Definium Therapeutics Rises 5.09% in Regular Trading, Phase 3 Clinical Success and Major Financing Boost Market Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Definium Therapeutics Rises 5.09% in Regular Trading, Phase 3 Clinical Success and Major Financing Boost Market Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-09 23:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 9, Definium Therapeutics rose 5.09% in regular trading, trading at $47.34 per share with turnover of $67.50 million.</p><p>The rally continues to be driven by the companys core product DT120 orally disintegrating tablet achieving positive topline results in its pivotal Phase 3 EMERGE study for major depressive disorder. The study met its primary endpoint and all key secondary efficacy endpoints, demonstrating statistically significant improvement over placebo with a favorable safety profile. Following the data readout, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.</p><p>Additionally, the company closed an upsized public offering of approximately 23.7 million shares at $34 each, raising gross proceeds of $805 million, including the full exercise of underwriter overallotment options. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. The combination of validated clinical data and strengthened financial position continues to support upward momentum in the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFTX","symbol_name":"Definium Therapeutics","start_time":0,"source_url":"","article_id":"1192883916","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192883916","pubTimestamp":1783612460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 9, Definium Therapeutics rose 5.09% in regular trading, trading at $47.34 per share with turnover of $67.50 million.The rally continues to be driven by the companys core product DT120 orally...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFTX":"Definium Therapeutics"},"translate_title":"动态提醒|Definium Therapeutics常规交易上涨5.09%，3期临床成功和重大融资提振市场信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":1},"content_text":"On July 9, Definium Therapeutics rose 5.09% in regular trading, trading at $47.34 per share with turnover of $67.50 million.The rally continues to be driven by the companys core product DT120 orally disintegrating tablet achieving positive topline results in its pivotal Phase 3 EMERGE study for major depressive disorder. The study met its primary endpoint and all key secondary efficacy endpoints, demonstrating statistically significant improvement over placebo with a favorable safety profile. Following the data readout, RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.Additionally, the company closed an upsized public offering of approximately 23.7 million shares at $34 each, raising gross proceeds of $805 million, including the full exercise of underwriter overallotment options. Proceeds are earmarked for R&D, potential commercialization preparation for DT120 ODT, and general corporate purposes. The combination of validated clinical data and strengthened financial position continues to support upward momentum in the stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192883916","isCrawlerRequest":true}